HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Follow-Up Questions
HOOKIPA Pharma Inc의 CEO는 누구입니까?
Dr. Malte Peters은 2023부터 회사에 합류한 HOOKIPA Pharma Inc의 Chief Executive Officer입니다.
HOOK 주식의 가격 성능은 어떻습니까?
HOOK의 현재 가격은 $0.9004이며, 전 거래일에 decreased 0% 하였습니다.
HOOKIPA Pharma Inc의 주요 사업 주제나 업종은 무엇입니까?
HOOKIPA Pharma Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
HOOKIPA Pharma Inc의 시가총액은 얼마입니까?
HOOKIPA Pharma Inc의 현재 시가총액은 $10.9M입니다
HOOKIPA Pharma Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 HOOKIPA Pharma Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다
